Endoscopic Fecal Microbiota Transplantation: “First-Line” Treatment for Severe Clostridium difficile Infection?
The DOI matches its Crossref record.
Abstract
Clostridium difficile infection (CDI) has been firmly thrust into the clinical spotlight, with the rising outbreaks of CDI in North America and Europe; emergence of the new, epidemic, hypervirulent NAP1/BI/027 strain; and markedly increased disease severity, higher colectomy rates (10.3%), and higher case-mortality rates than in decades past (34%).1–3 This strain has unique characteristics including increased production of toxin A and B, and expression of binary toxin, which contribute to these poorer outcomes.1 “Standard” treatment regimens of various antibiotics including vancomycin, metronidazole, nitazoxanide, or rifaximin, alone or in combination, fail to eradicate the infection in a proportion of patients who may go on to develop severe CDI with associated complications.4 To date, oral vancomycin and fidaxomicin are the only Food and Drug Administration-approved treatments for CDI.5 Disease recurrence is an increasing problem, with 20% to 60% of patients experiencing at least 1 recurrence within 2 to 4 weeks of completion of vancomycin treatment.6 Moreover, an increasing number of patients who require life-saving emergency colectomy experience persistent CDI postsurgery.7 There is a high and growing economic burden associated with CDI, resulting in considerable cost to patients, hospitals, national health expenditure, and insurers, with 1 report conservatively placing the cost of CDI management to the United States health care system at $1.1 billion annually.8 Published reports demonstrate that patients with CDI possess deficiencies in fecal flora composition, particularly of Bacteroides and Firmicutes, most likely as a result of earlier antibiotic usage9-11 and, in some as of yet unproven manner, these deficiencies in the microbiota facilitate colonization with C. difficile. Treatment of CDI with antibiotics fail to correct these floral deficiencies; even vancomycin is a broad-spectrum antibiotic, which targets Gram-positive anaerobic and aerobic bacteria. In contrast, fecal microbiota transplantation (FMT) is a simple, inexpensive, and highly curative method of not only eradicating the CDI but also of restoring the underlying microbiotic deficiencies.12 In this editorial, we propose that endoscopic FMT be considered among the “first-line” treatments for severe CDI. Transplantation of enteric bacteria was first performed by Fabricius of Acquapendente (1537–1619) and has been reported for many decades in the veterinary literature as “transfaunation.”13 In the modern era, FMT has been performed since 195814 and has now reached the stage where it is arguably the most reliable and effective form of C. difficile eradication therapy.12,15–17 Its increasing use in clinical practice has been associated with minimal to no adverse effects.15,16,18 FMT can be performed by various routes including nasogastric (NG) tube, nasojejunal tube, upper tract endoscopy (EGD), colonoscopically or by retention enema, depending on which is deemed safest for the individual patient. However, because a single colonoscopic infusion of human fecal suspension is extremely efficacious,9,16,18,19 easy to perform, rapidly and safely accomplished, delivers the “healthy” bacteria directly to the site where the vast majority of C. difficile is established, and able to be carried out in both inpatient and outpatient settings, we propose this as the first-line treatment of CDI in the majority of patients. Moreover, colonoscopic infusion allows direct simultaneous inspection of the mucosa, and determination of preferential sites for infusing larger amounts of donor stool, for example, in areas of diverticulosis. Not only is the infusion “low-tech,” with delivery of the fecal suspension through the colonoscope biopsy channel directly into the terminal ileum or colon, but no additional training to colonoscopy is required17; it is also cost effective, without additional charge, at present, to the cost of colonoscopy. The high cure rate of FMT is unparalleled, with 90% to 100% of reported patients achieving cure.15–17 Perhaps the most critical point is that only FMT restores the underlying flora deficiency,9,11 changing the composition of the recipient's intestinal microbiota in a durable manner.20 Given the growing epidemic, frequent catastrophic outcomes of CDI and lack of a uniformly reliable treatment, until an effective, safe, and curative therapy is developed, we propose that endoscopic FMT should be first-line treatment of recurrent and also severe CDI. For reasons stated above, colonoscopic FMT is preferred for the vast majority of CDI patients and if carried out early may prevent development of severe CDI. The subset of patients with CDI who are candidates for first-line endoscopic FMT generally includes patients who fall within the following categories: the most well studied and least arguable groups would be patients with recurrent CDI, “hard to manage” CDI, and those with pseudomembranous colitis. Next would be patients who have co
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Factors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Fecal microbiota transplantation and emerging applications
Borody, T. J., & Khoruts, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.244 · Cited by 677
Self-citationBrandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672
Self-citationGut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options
Hrncir, T. (2022) · Microorganisms · doi:10.3390/microorganisms10030578 · Cited by 433
An overview of fecal microbiota transplantation: techniques, indications, and outcomes
Brandt, L. J., & Aroniadis, O. C. (2013) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.03.1329 · Cited by 258
Self-citation
Metadata
- Authors
- Brandt, L. J., Borody, T. J., & Campbell, J.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2011-09
- Volume
- 45
- Issue
- 8
- Pages
- 655-657
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2084384600
- Cited by
- 73
- References
- 0
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endoscopic Fecal Microbiota Transplantation: “First-Line” Treatment for Severe Clostridium difficile Infection? https://app.cochat.ai/papers/10.1097/mcg.0b013e3182257d4f
- The paper
- Brandt, L. J., Borody, T. J., & Campbell, J. (2011). Endoscopic Fecal Microbiota Transplantation: “First-Line” Treatment for Severe Clostridium difficile Infection? Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e3182257d4f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.